PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 Inhibitor Takes On Pancreatic Cancer

PARP1 INHIBITORs PARP1 inhibitors are back in the headlines this week, as Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza posted positive Phase III results from a trial with pancreatic cancer patients—a notoriously difficult...
The Multiple Myeloma Landscape

The Multiple Myeloma Landscape

BLOOD CANCER: MULTIPLE MYELOMA Plasma cells are the antibody-producing cells of our immune system which happen to play a critical role in our defense against infections. In multiple myeloma, plasma cells begin to grow and divide in an uncontrolled manner, forming a...
Battling CLL: Venclexta

Battling CLL: Venclexta

 Pushing the Self-Destruct Button Breakthrough drug Venclexta charged onto the marketplace three months early to battle chronic lymphocytic leukemia. AbbVie’s (North Chicago, IL) and Roche’s (Basel, Switzerland) new therapy gained a quick approval after 80% of...
Targeting Breast Cancer

Targeting Breast Cancer

The Subtypes of Breast Cancer Hearing your doctor utter the words HER2-positive, HR-positive, triple-negative, or BRCA mutation can be devastating—even for the most resilient person. Simply put, all are linked to breast cancer. Breast cancer is complex and a diagnosis...